MYNZ
Mainz Biomed·NASDAQ
--
--(--)
--
--(--)
0.31 / 10
Underperform
The equity presents poor fundamental picture (0.3/10). Strengths include Fixed assets turnover ratio and Inventory turnover ratio, but headwinds are noted in Gross profit margin (%) and Current assets turnover ratio. This merits defensive consideration.
Analysis Checks(2/4)
Inventory turnover ratio
Value0.22
Score2/3
Weight779.06%
1M Return-2.37%
Value0.22
Score2/3
Weight779.06%
1M Return-2.37%
Current assets turnover ratio
Value0.05
Score1/3
Weight-94.23%
1M Return0.27%
Value0.05
Score1/3
Weight-94.23%
1M Return0.27%
Gross profit margin (%)
Value66.12
Score1/3
Weight-70.07%
1M Return0.22%
Value66.12
Score1/3
Weight-70.07%
1M Return0.22%
Fixed assets turnover ratio
Value0.21
Score3/3
Weight-514.76%
1M Return1.53%
Value0.21
Score3/3
Weight-514.76%
1M Return1.53%
Inventory turnover ratio
Value0.22
Score2/3
Weight779.06%
1M Return-2.37%
Value0.22
Score2/3
Weight779.06%
1M Return-2.37%
Gross profit margin (%)
Value66.12
Score1/3
Weight-70.07%
1M Return0.22%
Value66.12
Score1/3
Weight-70.07%
1M Return0.22%
Current assets turnover ratio
Value0.05
Score1/3
Weight-94.23%
1M Return0.27%
Value0.05
Score1/3
Weight-94.23%
1M Return0.27%
Fixed assets turnover ratio
Value0.21
Score3/3
Weight-514.76%
1M Return1.53%
Value0.21
Score3/3
Weight-514.76%
1M Return1.53%
Is MYNZ fundamentally strong?
- MYNZ scores 0.31/10 on fundamentals and holds a Premium valuation at present. Backed by its -194.76% ROE, -2874.69% net margin, -0.45 P/E ratio, 3.40 P/B ratio, and 88.13% earnings growth, these metrics solidify its Underperform investment rating.
